Literature DB >> 36008707

MC1R and melanin-based molecular probes for theranostic of melanoma and beyond.

Hui Shi1, Zhen Cheng2,3,4.   

Abstract

Malignant melanoma is accounting for most of skin cancer-associated mortality. The incidence of melanoma increased every year worldwide especially in western countries. Treatment efficiency is highly related to the stage of melanoma. Therefore, accurate staging and restaging play a pivotal role in the management of melanoma patients. Though 18F-fluorodeoxyglucose (18F-FDG) positron-emission tomography (PET) has been widely used in imaging of tumor metastases, novel radioactive probes for specific targeted imaging of both primary and metastasized melanoma are still desired. Melanocortin receptor 1 (MC1R) and melanin are two promising biomarkers specifically for melanoma, and numerous research groups including us have been actively developing a plethora of radioactive probes based on targeting of MC1R or melanin for over two decades. In this review, some of the MC1R-targeted tracers and melanin-associated molecular imaging probes developed in our research and others have been briefly summarized, and it provides a quick glance of melanoma-targeted probe design and may contribute to further developing novel molecular probes for cancer theranostics.
© 2022. The Author(s), under exclusive licence to Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Chinese Pharmacological Society.

Entities:  

Keywords:  MC1R; melanin; melanoma; molecular probes; radiotracers

Year:  2022        PMID: 36008707     DOI: 10.1038/s41401-022-00970-y

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   7.169


  116 in total

1.  The Growing Burden of Invasive Melanoma: Projections of Incidence Rates and Numbers of New Cases in Six Susceptible Populations through 2031.

Authors:  David C Whiteman; Adele C Green; Catherine M Olsen
Journal:  J Invest Dermatol       Date:  2016-02-20       Impact factor: 8.551

2.  The Rapid Rise in Cutaneous Melanoma Diagnoses.

Authors:  H Gilbert Welch; Benjamin L Mazer; Adewole S Adamson
Journal:  N Engl J Med       Date:  2021-01-07       Impact factor: 91.245

Review 3.  Melanoma.

Authors:  Dirk Schadendorf; Alexander C J van Akkooi; Carola Berking; Klaus G Griewank; Ralf Gutzmer; Axel Hauschild; Andreas Stang; Alexander Roesch; Selma Ugurel
Journal:  Lancet       Date:  2018-09-15       Impact factor: 79.321

4.  Melanogenesis affects overall and disease-free survival in patients with stage III and IV melanoma.

Authors:  Anna A Brożyna; Wojciech Jóźwicki; J Andrew Carlson; Andrzej T Slominski
Journal:  Hum Pathol       Date:  2013-06-19       Impact factor: 3.466

5.  Survival rates with uveal melanoma in the United States: 1973-1997.

Authors:  Arun D Singh; Allan Topham
Journal:  Ophthalmology       Date:  2003-05       Impact factor: 12.079

6.  Increasing burden of melanoma in the United States.

Authors:  Eleni Linos; Susan M Swetter; Myles G Cockburn; Graham A Colditz; Christina A Clarke
Journal:  J Invest Dermatol       Date:  2009-01-08       Impact factor: 8.551

Review 7.  Surgical Management of Primary Cutaneous Melanoma.

Authors:  Daniel Joyce; Joseph J Skitzki
Journal:  Surg Clin North Am       Date:  2019-10-28       Impact factor: 2.741

Review 8.  Epidemiology and Risk Factors of Melanoma.

Authors:  Stephanie Carr; Christy Smith; Jessica Wernberg
Journal:  Surg Clin North Am       Date:  2019-11-04       Impact factor: 2.741

9.  Vital signs: melanoma incidence and mortality trends and projections - United States, 1982-2030.

Authors:  Gery P Guy; Cheryll C Thomas; Trevor Thompson; Meg Watson; Greta M Massetti; Lisa C Richardson
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2015-06-05       Impact factor: 17.586

10.  The global burden of melanoma: results from the Global Burden of Disease Study 2015.

Authors:  C Karimkhani; A C Green; T Nijsten; M A Weinstock; R P Dellavalle; M Naghavi; C Fitzmaurice
Journal:  Br J Dermatol       Date:  2017-06-12       Impact factor: 9.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.